[1]

Rebello RJ, Oing C. Prostate cancer[J/OL]. Nat Rev Dis Primers, 2021, 7(1): 9[2022-01-07]. https://www.nature.com/articles/s41572-020-00243-0. DOI: 10.1038/s41572-020-00243-0.
[2] Lomas DJ, Ahmed HU.  All change in the prostate cancer diagnostic pathway[J]. Nat Rev Clin Oncol, 2020, 17(6): 372-381.   doi: 10.1038/s41571-020-0332-z
[3] 李孝媛, 李如帅, 尤琴琴, 等.  68Ga-PSMA-11 PET/MR多参数成像对初诊前列腺癌的诊断[J]. 中华核医学与分子影像杂志, 2021, 41(2): 98-103.   doi: 10.3760/cma.j.cn321828-20191125-00271
Li XY, Li RS, You QQ, et al.  68Ga-PSMA-11 PET/MR multiparameter imaging in the diagnosis of naive prostate cancer[J]. Chin J Nucl Med Mol Imaging, 2021, 41(2): 98-103.   doi: 10.3760/cma.j.cn321828-20191125-00271
[4] 付立武.  F-FDG PETCT最大标准摄取值联合血清PSA检查在前列腺癌诊断中的应用价值[J]. 临床医学, 2021, 41(2): 30-31.   doi: 10.19528/j.issn.1003-3548.2021.02.010
Fu LW.  Application value of F-FDG PETCT maximum standard uptake value combined with serum PSA examination in the diagnosis of prostate cancer[J]. Clin Med, 2021, 41(2): 30-31.   doi: 10.19528/j.issn.1003-3548.2021.02.010
[5] Naganawa S, Yoshikawa T, Yasaka K, et al.  Role of delayed-time-point imaging during abdominal and pelvic cancer screening using FDG-PET/CT in the general population[J]. Medicine (Baltimore), 2017, 96(46): e8832-.   doi: 10.1097/md.0000000000008832
[6] Chen YM, Huang G, Sun XG, et al.  Optimizing delayed scan time for FDG PET: comparison of the early and late delayed scan[J]. Nucl Med Commun, 2008, 29(5): 425-430.   doi: 10.1097/MNM.0b013e3282f4d389
[7] Parghane RV, Basu S.  Dual-time point 18F-FDG-PET and PET/CT for differentiating benign from malignant musculoskeletal lesions: opportunities and limitations[J]. Semin Nucl Med, 2017, 47(4): 373-391.   doi: 10.1053/j.semnuclmed.2017.02.009
[8] 雷银, 李天杰, 罗韬, 等.  多参数磁共振在前列腺癌诊断、评估中应用的研究进展[J]. 山东医药, 2020, 60(5): 111-114.   doi: 10.3969/j.issn.1002-266X.2020.05.030
Lei Y, Li TJ, Luo T, et al.  Research progress of multiparameter magnetic resonance in diagnosis and evaluation of prostate cancer[J]. Shandong Med J, 2020, 60(5): 111-114.   doi: 10.3969/j.issn.1002-266X.2020.05.030
[9] 伊丽努尔·艾力, 阿力木江·力提甫, 杨豫新, 等.  PET/CT和MRI参数对前列腺癌Gleason评分预测的价值探讨[J]. 医学影像学杂志, 2021, 31(5): 832-836.
Yilinuer AL, Alimujiang LTF, Yang YX, et al.  Value of PET/CT and MRI parameters in predicting Gleason score of prostate cancer[J]. J Med Imaging, 2021, 31(5): 832-836.
[10] Pietrzak AK, Kazmierska J, Marszalek A, et al.  Evaluation of physiologic and abnormal glucose uptake in palatine tonsils: differential diagnostics with sequential dual-time-point 2-deoxy-2-[18F]FDG PET/CT[J]. Q J Nucl Med Mol Imaging, 2020, 64(3): 299-306.   doi: 10.23736/s1824-4785.18.03065-0
[11]

Grisanti F, Zulueta J, Rosales JJ, et al. Diagnostic accuracy of visual analysis versus dual time-point imaging with 18F-FDG PET/CT for the characterization of indeterminate pulmonary nodules with low uptake[J/OL]. Rev Esp Med Nucl Imagen Mol (Engl Ed), 2021, 40(3): 155−160[2022-01-07]. https://www.sciencedirect.com/science/article/abs/pii/S2253654X20300664?via%3Dihub. DOI: 10.1016/j.remn.2020.03.019.
[12]

Mao WJ, Zhou J, Qiu L, et al. The added value of dual-time-point 18F-FDG PET/CT imaging in the diagnosis of colorectal cancer liver metastases[J]. Abdom Radiol (NY), 2020, 45(4): 1075−1081[2022-01-07]. https://link.springer.com/article/10.1007/s00261-019-02396-3. DOI: 10.1007/s00261-019-02396-3.
[13] Cheng G, Torigian DA, Zhuang H, et al.  When should we recommend use of dual time-point and delayed time-point imaging techniques in FDG PET[J]. Eur J Nucl Med Mol Imaging, 2013, 40(5): 779-787.   doi: 10.1007/s00259-013-2343-9
[14] 陈雯, 姚稚明, 张建飞.  18F-FDG PET/CT延迟显像对前列腺FDG摄取异常增高的鉴别诊断价值[J]. 临床和实验医学杂志, 2019, 18(14): 1496-1499.   doi: 10.3969/j.issn.1671-4695.2019.14.012
Chen W, Yao ZM, Zhang JF.  Value of the dual time scan with 18F-FDG PET/CT in differential diagnosis of the incidental hypermetabolic lesions in prostate[J]. J Clin Exp Med, 2019, 18(14): 1496-1499.   doi: 10.3969/j.issn.1671-4695.2019.14.012
[15] 郝珊瑚, 张国旭, 王志国, 等.  18F-FDG PET/CT利尿剂延迟显像对前列腺肿瘤的诊断价值[J]. 现代肿瘤医学, 2014, 22(5): 1154-1156.   doi: 10.3969/j.issn.1672-4992.2014.05.53
Hao SH, Zhang GX, Wang ZG, et al.  Delayed diuretic 18F-FDG PET/CT scan for differentiating malignant from benign prostate lesions[J]. Mod Oncol, 2014, 22(5): 1154-1156.   doi: 10.3969/j.issn.1672-4992.2014.05.53
[16]

Mortensen MA, Vilstrup MH, Poulsen MH, et al. A prospective study on dual time 18F-FDG-PET/CT in high-risk prostate cancer patients[J/OL]. BMC Res Notes, 2018, 11(1): 871[2022-01-07]. https://bmcresnotes.biomedcentral.com/articles/10.1186/s13104-018-3985-2. DOI: 10.1186/s13104-018-3985-2.
[17] 吴凌梅, 杨晖, 王瑞民, 等.  18F-FDG PET/CT显像联合血清学指标在前列腺癌原发灶诊断及骨转移评估中的价值研究[J]. 中国医学装备, 2020, 17(2): 53-57.   doi: 10.3969/J.ISSN.1672-8270.2020.02.015
Wu LM, Yang H, Wang RM, et al.  Research on the value of 18F-FDG PET/CT imaging combined with serological indicators in diagnosing primary lesion of prostate cancer and evaluating osseous metastasis[J]. China Med Equip, 2020, 17(2): 53-57.   doi: 10.3969/J.ISSN.1672-8270.2020.02.015
[18] Meziou S, Ringuette Goulet C, Hovington H, et al.  GLUT1 expression in high-risk prostate cancer: correlation with 18F-FDG PET/CT and clinical outcome[J]. Prostate Cancer Prostatic Dis, 2020, 23(3): 441-448.   doi: 10.1038/s41391-020-0202-x